Drug Trial Radar · NCT04998851
A Study Evaluating B Cell Levels In Infants Of Lactating Women With CIS Or MS Receiving Ocrelizumab
Last checked: Nov 20, 2026Latest source record: Jan 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
26
Actual
Start
Sep 16, 2021
Primary completion
Mar 29, 2024
Study completion Jan 13, 2025
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- Collaborators
- PPD Development, LP; Laboratory Corporation of America; Illingworth Research Group
- First posted
- Aug 10, 2021
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Other
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years, up to 40 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will evaluate the pharmacokinetics of ocrelizumab in the breastmilk of lactating women with clinically isolated syndrome (CIS) or multiple sclerosis (MS) \[in line with the locally approved indications\] treated with ocrelizumab, by assessing the concentration of ocrelizumab in mature breastmilk, as well as the corresponding exposure and pharmacodynamic effects (blood B cell levels) in the infants.
Conditions
- Multiple Sclerosis
- Clinically Isolated Syndrome
Interventions
OcrelizumabDrug
Women will receive the ocrelizumab dose regimen as per the locally-approved label. The ocrelizumab dose will be administered as an initial split dose of two 300 mg infusions separated by 14 days or a single 600 mg infusion according to the local prescribing information.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Infants With B Cell Levels (Cluster of Differentiation 19 [CD19+] Cells) Below the Lower Limit of Normal (LLN) Measured at Day 30 After the Mother's First Ocrelizumab Postpartum InfusionTime frame: At Day 30
- Estimated Average Oral Daily Infant Dosage (ADID)Time frame: Up to Day 60
Locations
8 sites in 3 countries. Site status is shown where the registry gives one.
University of California San Francisco
San Francisco, California
University Of Colorado
Aurora, Colorado
Northwestern Memorial Hospital
Chicago, Illinois
Brigham and Womens Hospital
Boston, Massachusetts
Memorial Healthcare Institute for Neurosciences and Multiple Sclerosis
Owosso, Michigan
Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania
Hosp. Clinico San Carlos
Madrid, Spain
Queen Mary University of London
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.